Back to Report Store Home

Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes

  • Published: Aug-2016
  • Report Code: GBIHC356MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Pharmaceutical Market, Global, Innovation Trends in Product Approvals, 1987–2012 5

Figure 2: Pharmaceutical Market, Global, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 7

Figure 3: Pain Market, Global, Treatment Algorithm 15

Figure 4: Pain Market, Global, WHO Analgesic Ladder 16

Figure 5: Pain Market, Global, Marketed Products by Molecule Type and Molecular Target, 2016 18

Figure 6: Pharmaceutical Market, Global, Developmental Pipeline Overview, 2016 20

Figure 7: Pain Market, Global, Developmental Pipeline Overview, 2016 21

Figure 8: Pain Market, Global, Developmental Pipeline Molecular Target Categories, 2016 22

Figure 9: Pain Market, Global, Molecular Target Category Comparison of Pipeline and Marketed Products, 2016 23

Figure 10: Pain Market, Global, Molecular Target Category Comparison of Pipeline First-in-Class and Established Molecular Targets, 2016 25

Figure 11: Pain Market, Global, Level of First-in-Class Innovation by Stage of Development (%), 2016 26

Figure 12: Pain Market, Global, Level of First-in-Class Innovation by Molecular Target (%), 2016 26

Figure 13: Pain Market, Global, Total Pipeline Products by Pain Subtype and Stage of Development, 2016 27

Figure 14: Pain Market, Global, Total Pipeline Products by Pain Subtype and Stage of Development, 2016 27

Figure 15: Pain Market, Global, First-in-Class Pipeline Products by Pain Subtype and Molecular Target, 2016 28

Figure 16: Pain Market, Global, First-in-Class Pipeline Products by Pain Subtype and Stage of Development, 2016 29

Figure 17: Pain Market, Global, First-in-Class Products in the Pipeline Part 1, 2016 30

Figure 18: Pain Market, Global, First-in-Class Products in the Pipeline Part 2, 2016 31

Figure 19: Pain Market, Global, First-in-Class Molecular Target Analysis Matrix Part 1, 2016 33

Figure 20: Pain Market, Global, First-in-Class Molecular Target Analysis Matrix Part 2, 2016 34

Figure 21: Pain Market, Global, Pipeline Programs Targeting XXX, 2016 37

Figure 22: Pain Market, Global, Pipeline Programs Targeting XXX, 2016 37

Figure 23: Pain Market, Global, Pipeline Programs Targeting XXX, 2016 38

Figure 24: Pain Market, Global, Pipeline Programs Targeting XXX, 2016 41

Figure 25: Pain Market, Global, Pipeline Programs Targeting XXX, 2016 43

Figure 26: Pain Market, Global, Pipeline Programs Targeting XXX, 2016 44

Figure 27: Pain Market, Global, Pipeline Programs Targeting XXX, 2016 46

Figure 28: Pain Market, Global, Pipeline Programs Targeting XXX, 2016 46

Figure 29: Pain Market, Global, Pipeline Programs Targeting XXX, 2016 47

Figure 30: Pharmaceutical Market, Global, Industry-Wide Deals by Stage of Development, 2006–2014 48

Figure 31: Pharmaceutical Market, Global, Industry Licensing Deal Values by Stage of Development, 2006–2014 49

Figure 32: Pain Market, Global, Licensing Deals by Region and Value, 2006–2016 50

Figure 33: Pain Market, Global, Licensing Deals by Stage of Development and Value, 2006–2016 51

Figure 34: Pain Market, Global, Licensing Deals by Stage of Development and Molecule Type, 2006–2016 51

Figure 35: Pain Market, Global, Licensing Deals by Stage of Development and Molecular Target, 2006–2016 52

Figure 36: Pain Market, Global, Summary of Licensing Deals Valued Above $100m, 2006–2016 53

Figure 37: Pain Market, Global, Co-development Deals by Region and Value, 2006–2015 54

Figure 38: Pain Market, Global, Co-Development Deals by Stage of Development and Value, 2006–2016 55

Figure 39: Pain Market, Global, Co-Development Deals by Stage of Development and Molecule Type, 2006–2016 55

Figure 40: Pain Market, Global, Co-Development Deals by Stage of Development and Molecular Target, 2006–2016 56

Figure 41: Pain Market, Global, Summary of Co-development Deals Valued Above $100m, 2006–2016 57

Figure 42: Pain Market, Global, List of Pipeline Products With Prior Licensing or Co-Development Deal Involvement, 2016 58

Figure 43: Pain Market, Global, List of Pipeline Products Without Prior Licensing or Co-Development Deal Involvement, 2016 59

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards